Children's oncology Group's 2013 blueprint for research

Rare tumors

Carlos Rodriguez-Galindo, Mark Krailo, Lindsay Frazier, Murali Chintagumpala, James Amatruda, Howard Katzenstein, Marcio Malogolowkin, Logan Spector, Farzana Pashankar, Rebecka Meyers, Gail Tomlinson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.

Original languageEnglish (US)
Pages (from-to)1016-1021
Number of pages6
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Germ Cell and Embryonal Neoplasms
Retinoblastoma
Research
Neoplasms
Hepatoblastoma
Phase III Clinical Trials
Epidemiologic Studies
Liver
Therapeutics

Keywords

  • Germ cell tumors
  • Hepatoblastoma
  • Rare cancers
  • Retinoblastoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Rodriguez-Galindo, C., Krailo, M., Frazier, L., Chintagumpala, M., Amatruda, J., Katzenstein, H., ... Tomlinson, G. (2013). Children's oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood and Cancer, 60(6), 1016-1021. https://doi.org/10.1002/pbc.24428

Children's oncology Group's 2013 blueprint for research : Rare tumors. / Rodriguez-Galindo, Carlos; Krailo, Mark; Frazier, Lindsay; Chintagumpala, Murali; Amatruda, James; Katzenstein, Howard; Malogolowkin, Marcio; Spector, Logan; Pashankar, Farzana; Meyers, Rebecka; Tomlinson, Gail.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 06.2013, p. 1016-1021.

Research output: Contribution to journalArticle

Rodriguez-Galindo, C, Krailo, M, Frazier, L, Chintagumpala, M, Amatruda, J, Katzenstein, H, Malogolowkin, M, Spector, L, Pashankar, F, Meyers, R & Tomlinson, G 2013, 'Children's oncology Group's 2013 blueprint for research: Rare tumors', Pediatric Blood and Cancer, vol. 60, no. 6, pp. 1016-1021. https://doi.org/10.1002/pbc.24428
Rodriguez-Galindo C, Krailo M, Frazier L, Chintagumpala M, Amatruda J, Katzenstein H et al. Children's oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood and Cancer. 2013 Jun;60(6):1016-1021. https://doi.org/10.1002/pbc.24428
Rodriguez-Galindo, Carlos ; Krailo, Mark ; Frazier, Lindsay ; Chintagumpala, Murali ; Amatruda, James ; Katzenstein, Howard ; Malogolowkin, Marcio ; Spector, Logan ; Pashankar, Farzana ; Meyers, Rebecka ; Tomlinson, Gail. / Children's oncology Group's 2013 blueprint for research : Rare tumors. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 1016-1021.
@article{8e1b8c3016754c59ae472afe4018dd7d,
title = "Children's oncology Group's 2013 blueprint for research: Rare tumors",
abstract = "In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20{\%} for children with advanced carcinomas to >95{\%} for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.",
keywords = "Germ cell tumors, Hepatoblastoma, Rare cancers, Retinoblastoma",
author = "Carlos Rodriguez-Galindo and Mark Krailo and Lindsay Frazier and Murali Chintagumpala and James Amatruda and Howard Katzenstein and Marcio Malogolowkin and Logan Spector and Farzana Pashankar and Rebecka Meyers and Gail Tomlinson",
year = "2013",
month = "6",
doi = "10.1002/pbc.24428",
language = "English (US)",
volume = "60",
pages = "1016--1021",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's oncology Group's 2013 blueprint for research

T2 - Rare tumors

AU - Rodriguez-Galindo, Carlos

AU - Krailo, Mark

AU - Frazier, Lindsay

AU - Chintagumpala, Murali

AU - Amatruda, James

AU - Katzenstein, Howard

AU - Malogolowkin, Marcio

AU - Spector, Logan

AU - Pashankar, Farzana

AU - Meyers, Rebecka

AU - Tomlinson, Gail

PY - 2013/6

Y1 - 2013/6

N2 - In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.

AB - In the US, approximately 2,000 children are diagnosed with rare cancers each year, with 5-year survival ranging from <20% for children with advanced carcinomas to >95% for children with intraocular retinoblastoma or localized germ cell tumors. During the last years, 12 clinical studies have been successfully completed in children with retinoblastoma, liver tumors, germ cell tumors, and infrequent malignancies, including therapeutic, epidemiologic, and biologic studies. Current efforts are centered in the development of large international collaborations to consolidate evidence-based definitions and risk stratifications that will support international Phase 3 clinical trials in germ cell tumors, hepatoblastoma, and other rare cancers.

KW - Germ cell tumors

KW - Hepatoblastoma

KW - Rare cancers

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=84876441093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876441093&partnerID=8YFLogxK

U2 - 10.1002/pbc.24428

DO - 10.1002/pbc.24428

M3 - Article

VL - 60

SP - 1016

EP - 1021

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -